Table 2.

Univariate and multivariate analyses for the overall survival (Cox hazard model)

	Univariate			Multivariate
	HR	95% CI	P	HR	95% CI	P
Age ≥ 60 years	1.23	0.94–1.62	0.13
Estrogen receptor negative	1.53	1.14–2.07	0.005	1.79	1.29–2.48	<0.001
Recurrent disease	1.13	0.84-1.52	0.43
Central nervous system metastasis	0.99	0.51–1.94	0.98
Bone metastasis	1.40	1.06–1.85	0.018	1.51	1.10–2.07	0.011
Lung metastasis	1.04	0.78–1.37	0.81
Pleura/lymphangiopathy metastasis	1.25	0.90–1.73	0.19
Lymph node metastasis	1.07	0.80–1.43	0.66
Liver metastasis	1.85	1.40-2.44	< 0.001	1.61	1.14-2.28	0.007
Visceral metastasis	1.54	1.15-2.07	0.004	1.22	0.83-1.80	0.31
≥ 3 metastatic sites	1.43	1.08–1.88	0.013	1.26	0.91–1.75	0.16
Perioperative chemotherapy a	1.37	1.05-1.80	0.022	1.66	1.23-2.24	0.001
Disease-free interval<24 months	1.37	1.03–1.80	0.029	1.39	1.04–1.87	0.028
Therapy
Eribulin vs. non-Eribulin	1.11	0.84-1.47	0.47	0.85	0.63-1.15	0.29
Early-line eribulin b vs. non-Eribulin	1.28	0.92-1.78	0.15
Late-line eribulin c vs. non-Eribulin	0.96	0.69-1.33	0.79

CI: confidence interval, HR: hazard ratio

^aTreatment included anthracycline and/or taxane

^bEarly line includes first or second lines of therapy

^cLate line includes third or later lines of therapy